Structure of vaccinia virus thymidine kinase in complex with dTTP: Insights for drug design

BMC Structural Biology

Volumn 6, Issue , 2006, Pages

  El Omari, Kamel ^a   Solaroli, Nicola ^b   Karlsson, Anna ^b   Balzarini, Jan ^c   Stammers, David K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; METHANOCARBATHYMINE; NUCLEOSIDE DERIVATIVE; THYMIDINE KINASE; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; DRUG DESIGN; DRUG SELECTIVITY; ENZYME KINETICS; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYME SUBUNIT; STRUCTURE ANALYSIS; VACCINIA VIRUS;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; KINETICS; LIGANDS; MACROMOLECULAR SUBSTANCES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; THYMIDINE KINASE; THYMINE NUCLEOTIDES; VACCINIA VIRUS; VIRAL PROTEINS;

HERPES; VACCINIA VIRUS; VARIOLA; VARIOLA VIRUS;

EID: 33750999341     PISSN: 14726807     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-6-22     Document Type: Article

References (40)

1. Black ME, Hruby DE: Quaternary structure of vaccinia virus thymidine kinase. Biochem Biophys Res Commun 1990, 169(3):1080-1086.
2. Esposito JJ, Knight JC: Nucleotide sequence of the thymidine kinase gene region of monkeypox and variola viruses. Virology 1984, 135(2):561-567.
3. Flemington E, Bradshaw HDJ, Traina-Dorge V, Slagel V, Deininger PL: Sequence, structure and promoter characterization of the human thymidine kinase gene. Gene 1987, 52(2-3):267-277.
4. Lin PF, Lieberman HB, Yeh DB, Xu T, Zhao SY, Ruddle FH: Molecular cloning and structural analysis of murine thymidine kinase genomic and cDNA sequences. Mol Cell Biol 1985, 5(11):3149-3156.
5. Hruby DE: Inhibition of vaccinia virus thymidine kinase by the distal products of its own metabolic pathway. Virus Res 1985, 2(2):151-156.
6. Arner ES, Eriksson S: Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995, 67(2):155-186.
7. De Clercq E: Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 2004, 68(12):2301-2315.
8. Vogt J, Perozzo R, Pautsch A, Prota A, Schelling P, Pilger B, Folkers G, Scapozza L, Schulz GE: Nucleoside binding site of herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography. Proteins 2000, 41(4):545-553.
9. Kohn DB, Sadelain M, Dunbar C, Bodine D, Kiem HP, Candotti F, Tisdale J, Riviere I, Blau CA, Richard RE, Sorrentino B, Nolta J, Malech H, Brenner M, Cornetta K, Cavagnaro J, High K, Glorioso J: American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003, 8(2):180-187.
10. Breman JG, Arita I: The confirmation and maintenance of smallpox eradication. N Engl J Med 1980, 303(22):1263-1273.
11. Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, Kazmierczak JJ, Stratman EJ, Li Y, Fairley JA, Swain GR, Olson VA, Sargent EK, Kehl SC, Frace MA, Kline R, Foldy SL, Davis JP, Damon IK: The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004, 350(4):342-350.
12. Moore ZS, Seward JF, Lane JM: Smallpox. Lancet 2006, 367(9508):425-435.
13. Ratner LH, Lane JM, Vicens CN: Complications of smallpox vaccination: surveillance during an island-wide program in Puerto Rico, 1967-1968. Am J Epidemiol 1970, 91(3):278-285.
14. Mellin H, Neff JM, Garber H, Lane JM: Complications of smallpox vaccination, Maryland 1968. Johns Hopkins Med J 1970, 126(3):160-168.
15. Lane JM, Ruben FL, Abrutyn E, Millar JD: Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. Jama 1970, 212(3):441-444.
16. De Clercq E: Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology 1997, 40(5-6):295-303.
17. Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW: Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 2002, 46(5):1329-1335.
18. Naesens L, De Clercq E: Recent developments in herpesvirus therapy. Herpes 2001, 8(1):12-16.
19. Walter TS, Diprose JM, Mayo CJ, Siebold C, Pickford MG, Carter L, Sutton GC, Berrow NS, Brown J, Berry IM, Stewart-Jones GB, Grimes JM, Stammers DK, Esnouf RM, Jones EY, Owens RJ, Stuart DI, Harlos K: A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. Acta Crystallogr D Biol Crystallogr 2005, 61(Pt 6):651-657.
20. Wild K, Bohner T, Folkers G, Schulz GE: The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci 1997, 6(10):2097-2106.
21. Bird LE, Ren J, Wright A, Leslie KD, Degreve B, Balzarini J, Stammers DK: Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem 2003, 278(27):24680-24687.
22. Welin M, Kosinska U, Mikkelsen NE, Carnrot C, Zhu C, Wang L, Eriksson S, Munch-Petersen B, Eklund H: Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc Natl Acad Sci U S A 2004, 101(52):17970-17975.
23. Birringer MS, Claus MT, Folkers G, Kloer DP, Schulz GE, Scapozza L: Structure of a type II thymidine kinase with bound dTTP. FEBS Lett 2005, 579(6):1376-1382.
24. Kosinska U, Carnrot C, Eriksson S, Wang L, Eklund H: Structure of the substrate complex of thymidine kinase from Ureaplasma urealyticum and investigations of possible drug targets for the enzyme. Febs J 2005, 272(24):6365-6372.
25. Fan X, Zhang X, Zhou L, Keith KA, Prichard MN, Kern ER, Torrence PF: Towards orthopoxvirus coutermeasures: a novel heteromorphic nucleoside of unusual structure. J Med Chem 2006, 49(14):4052-4054.
26. Vallee BL, Auld DS: Functional zinc-binding motifs in enzymes and DNA-binding proteins. Faraday Discuss 1992:47-65.
27. Smee DF, Wandersee MK, Bailey KW, Wong MH, Chu CK, Gadthula S, Sidwell RW: Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antiviral Res 2006.
28. Prichard MN, Keith KA, Quenelle DC, Kern ER: Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob Agents Chemother 2006, 50(4):1336-1341.
29. Marquez VE, Ben-Kasus T, Barchi JJJ, Green KM, Nicklaus MC, Agbaria R: Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker. J Am Chem Soc 2004, 126(2):543-549.
30. Schelling P, Claus MT, Johner R, Marquez VE, Schulz GE, Scapozza L: Biochemical and structural characterization of (South)-methanocarbathymidine that specifically inhibits growth of herpes simplex virus type 1 thymidine kinase-transduced osteosarcoma cells. J Biol Chem 2004, 279(31):32832-32838.
31. Black ME, Hruby DE: Site-directed mutagenesis of a conserved domain in vaccinia virus thymidine kinase. Evidence for a potential role in magnesium binding. J Biol Chem 1992, 267(10):6801-6806.
32. Black ME, Hruby DE: Identification of the ATP-binding domain of vaccinia virus thymidine kinase. J Biol Chem 1990, 265(29):17584-17592.
33. Black ME, Hruby DE: A single amino acid substitution abolishes feedback inhibition of vaccinia virus thymidine kinase. J Biol Chem 1992, 267(14):9743-9748.
34. Otwinowski Z, Minor W: Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1996, 276:307-326.
35. Vagin A, Teplyakov A: MOLREP: an automated program for molecular replacement. J Appl Cryst 1997, 30:1022-1025.
36. Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004, 60(Pt 12 Pt 1):2126-2132.
37. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL: Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998, 54(Pt 5):905-921.
38. Murshudov GN, Vagin AA, Dodson EJ: Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997, 53(Pt 3):240-255.
39. Winn MD, Isupov MN, Murshudov GN: Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr D Biol Crystallogr 2001, 57(Pt 1):122-133.
40. Stuart DI, Levine M, Muirhead H, Stammers DK: Crystal structure of cat muscle pyruvate kinase at a resolution of 2.6 A. J Mol Biol 1979, 134(1):109-142.